MedPath

Efficacy of platelet-rich plasma injection in combination with tranexamic acid compared with tranexamic acid injection alone inthe treatment of macular amyloidosis

Phase 1
Recruiting
Conditions
Macular amyloidosis.
Other amyloidosis
E85.8
Registration Number
IRCT20220808055641N4
Lead Sponsor
Tehran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
10
Inclusion Criteria

Clinical diagnosis of macular amyloidosis
Age above 18 years old

Exclusion Criteria

Pregnancy
Breastfeeding
Coagulation disorders

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Improvement of macular amyloidosis. Timepoint: The beginning of the study and 1 month after the start of the study and 3 months after the start of the study. Method of measurement: sonography;visioface;biometery;cutometery,physician global assessment score;patient global assessment score.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath